Xinwei Jiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xinwei Jiao has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Hongyu Li
9 shared publicationsTing Wang
7 shared publicationsChuyao Wang
6 shared publicationsXiuyun Li
Department of Ophthalmology, Affiliated Hospital of Shandong Second Medical University, School of Clinical Medicine, Shandong Second Medical University, Weifang 261053, China
6 shared publications- Zhijie Li
International Ocular Surface Research Center, Institute of Ophthalmology, and Key Laboratory for Regenerative Medicine, Jinan University, Guangzhou, China; Department of Ophthalmology, The First Affiliated Hospital of Jinan University, Guangzhou, China
6 shared publications - Aijun Deng
Department of Ophthalmology, Affiliated Hospital of Shandong Second Medical University, School of Clinical Medicine, Shandong Second Medical University, Weifang 261053, China
4 shared publications
Latest Publications
- 28 October 2026
- Published by Elsevier in Experimental Eye Research
- Vol. 273
Unraveling neuro-immune crosstalk in dry eye disease: Corneal neuropathy, lacrimal dysfunction, and therapeutic horizons
- 28 October 2026
- Published by Elsevier in Experimental Eye Research
- Vol. 273
Unraveling neuro-immune crosstalk in dry eye disease: Corneal neuropathy, lacrimal dysfunction, and therapeutic horizons
- 28 May 2026
- Published by Elsevier in Experimental Eye Research
- Vol. 270, 111096
Precision management of autoimmune ocular complications: Th17 mechanisms and therapeutic innovations
- 28 May 2026
- Published by Elsevier in Experimental Eye Research
- Vol. 270, 111096
Precision management of autoimmune ocular complications: Th17 mechanisms and therapeutic innovations
- 20 May 2026
- Published by Elsevier in The Ocular Surface
- Vol. 41, 116-125
Nobiletin restores corneal circadian transcriptome organization and mitigates ocular surface pathology in high-fructose-induced metabolic dysfunction
- 20 May 2026
- Published by Elsevier in The Ocular Surface
- Vol. 41, 116-125
Nobiletin restores corneal circadian transcriptome organization and mitigates ocular surface pathology in high-fructose-induced metabolic dysfunction
- 17 March 2026
- Published by Wiley in Cell Biochemistry and Function
- Vol. 44 (3) , e70195
Unveiling the 12‐Hour Ultradian Rhythm: Biological Foundations, Mechanistic Insights, and Potential Applications
The ~12‐h ultradian rhythm (circasemidian) represents an evolutionarily conserved temporal architecture that complements the canonical 24‐h circadian clock. Over the past 5 years, mounting evidence has revealed its ubiquity across biological kingdoms, from tidal marine organisms and cyanobacteria to plants, microbiomes, and mammals, including humans, manifesting as intrinsic oscillations in gene expression, metabolism, and behavior that often persist independently of circadian control. In mammals, this rhythm is driven by a cell‐autonomous oscillator centered on the XBP1s (X‐box binding protein 1)/IRE1α (Inositol requiring enzyme 1 alpha) axis, orchestrating endoplasmic reticulum stress responses and lipid homeostasis through negative feedback regulation, further reinforced by metabolic coupling and bidirectional crosstalk with circadian pathways. Functionally, 12‐h oscillations act as a secondary temporal layer that ensures bimodal photostatic and energetic homeostasis, synchronizing multi‐organ physiology across the day–night transition. Pathologically, disruption of this rhythm contributes to metabolic syndromes (e.g., NAFLD (non‐alcoholic fatty liver disease), diabetes), neuropsychiatric disorders (e.g., schizophrenia), and age‐related dysfunctions, particularly within ocular and immune systems. Despite accumulating correlative and model‐based evidence, causal mechanisms remain insufficiently defined, and human data are limited. Future work integrating multi‐omics chrono profiling, comparative genomics, and clinical chronotherapeutic trials will be critical to delineate this semidiurnal oscillator's molecular architecture and translational potential, thereby advancing precision chrono medicine and expanding the current paradigm of biological timing.
- 17 March 2026
- Published by Wiley in Cell Biochemistry and Function
- Vol. 44 (3) , e70195
Unveiling the 12‐Hour Ultradian Rhythm: Biological Foundations, Mechanistic Insights, and Potential Applications
The ~12‐h ultradian rhythm (circasemidian) represents an evolutionarily conserved temporal architecture that complements the canonical 24‐h circadian clock. Over the past 5 years, mounting evidence has revealed its ubiquity across biological kingdoms, from tidal marine organisms and cyanobacteria to plants, microbiomes, and mammals, including humans, manifesting as intrinsic oscillations in gene expression, metabolism, and behavior that often persist independently of circadian control. In mammals, this rhythm is driven by a cell‐autonomous oscillator centered on the XBP1s (X‐box binding protein 1)/IRE1α (Inositol requiring enzyme 1 alpha) axis, orchestrating endoplasmic reticulum stress responses and lipid homeostasis through negative feedback regulation, further reinforced by metabolic coupling and bidirectional crosstalk with circadian pathways. Functionally, 12‐h oscillations act as a secondary temporal layer that ensures bimodal photostatic and energetic homeostasis, synchronizing multi‐organ physiology across the day–night transition. Pathologically, disruption of this rhythm contributes to metabolic syndromes (e.g., NAFLD (non‐alcoholic fatty liver disease), diabetes), neuropsychiatric disorders (e.g., schizophrenia), and age‐related dysfunctions, particularly within ocular and immune systems. Despite accumulating correlative and model‐based evidence, causal mechanisms remain insufficiently defined, and human data are limited. Future work integrating multi‐omics chrono profiling, comparative genomics, and clinical chronotherapeutic trials will be critical to delineate this semidiurnal oscillator's molecular architecture and translational potential, thereby advancing precision chrono medicine and expanding the current paradigm of biological timing.
- 6 January 2026
- Published by Elsevier in Experimental Eye Research
- Vol. 264, 110852
Sweet poison for the eyes: High-Fructose diets as drivers of metabolic disruption and ocular diseases - Insights and therapeutic horizons
- 6 January 2026
- Published by Elsevier in Experimental Eye Research
- Vol. 264, 110852
Sweet poison for the eyes: High-Fructose diets as drivers of metabolic disruption and ocular diseases - Insights and therapeutic horizons
- 18 December 2025
- Published by Elsevier in Experimental Eye Research
- Vol. 263, 110815
Retinal microvascular biomarkers for cardiovascular risk stratification: Insights from OCTA and AI
- 18 December 2025
- Published by Elsevier in Experimental Eye Research
- Vol. 263, 110815
Retinal microvascular biomarkers for cardiovascular risk stratification: Insights from OCTA and AI
- 18 September 2025
- Published by Elsevier in Experimental Eye Research
- Vol. 261, 110644
Diabetic retinopathy as a sentinel of systemic vascular dysfunction: Shared molecular mechanisms with cardiovascular disease
- 18 September 2025
- Published by Elsevier in Experimental Eye Research
- Vol. 261, 110644
Diabetic retinopathy as a sentinel of systemic vascular dysfunction: Shared molecular mechanisms with cardiovascular disease
- Open Access
Progressive gut microbiota shifts and functional alterations across aging stages and frailty in mice
- 3 June 2025
- Published by Elsevier in Experimental Eye Research
- Vol. 258, 110472
Disruption of the 12-hour ultradian rhythm in ocular surface microbiota of T2DM C57BL/6J mice
- 3 June 2025
- Published by Elsevier in Experimental Eye Research
- Vol. 258, 110472
Disruption of the 12-hour ultradian rhythm in ocular surface microbiota of T2DM C57BL/6J mice
- 13 February 2025
- Published by Elsevier in Experimental Eye Research
- Vol. 253, 110282
Impact of streptozotocin-induced type 1 and type 2 diabetes on ocular surface microbial signatures in C57BL/6J mice
- 13 February 2025
- Published by Elsevier in Experimental Eye Research
- Vol. 253, 110282
Impact of streptozotocin-induced type 1 and type 2 diabetes on ocular surface microbial signatures in C57BL/6J mice